Next Article in Journal
End-Stage Kidney Disease Resulting from Atypical Hemolytic Uremic Syndrome after Receiving AstraZeneca SARS-CoV-2 Vaccine: A Case Report
Next Article in Special Issue
The Integrated Consideration of Vaccine Platforms, Adjuvants, and Delivery Routes for Successful Vaccine Development
Previous Article in Journal
Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms
Previous Article in Special Issue
Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 3
10.3390/vaccines11030674
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Candida parapsilosis Cell Wall Proteome Characterization and Effectiveness against Hematogenously Disseminated Candidiasis in a Murine Model

by
Xiaolong Gong
1,
Vartika Srivastava
1,
Previn Naicker
2,
Amber Khan
3 and
Aijaz Ahmad
1,4,*
1
Clinical Microbiology and Infectious Diseases, School of Pathology, Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa
2
NextGen Health, Council for Scientific and Industrial Research, Pretoria 0184, South Africa
3
The Scintillon Institute, 6404 Nancy Ridge Drive, San Diego, CA 92121, USA
4
Infection Control, Charlotte Maxeke Johannesburg Academic Hospital, National Health Laboratory Service, Johannesburg 2193, South Africa
*
Author to whom correspondence should be addressed.
Vaccines 2023, 11(3), 674; https://doi.org/10.3390/vaccines11030674
Submission received: 22 February 2023 / Revised: 10 March 2023 / Accepted: 13 March 2023 / Published: 16 March 2023
(This article belongs to the Special Issue New Trends in Vaccine Characterization, Formulations, and Development)
Browse Figures
Review Reports Versions Notes

Abstract

:
Candida parapsilosis poses huge treatment challenges in the clinical settings of South Africa, and often causes infections among immunocompromised patients and underweight neonates. Cell wall proteins have been known to play vital roles in fungal pathogenesis, as these are the first points of contact toward environments, the host, and the immune system. This study characterized the cell wall immunodominant proteins of pathogenic yeast C. parapsilosis and evaluated their protective effects in mice, which could add value in vaccine development against the rising C. parapsilosis infections. Among different clinical strains, the most pathogenic and multidrug-resistant C. parapsilosis isolate was selected based on their susceptibility towards antifungal drugs, proteinase, and phospholipase secretions. Cell wall antigens were prepared by β-mercaptoethanol/ammonium bicarbonate extraction from selected C. parapsilosis strains. Antigenic proteins were identified using LC–MS/MS, where 933 proteins were found, with 34 being immunodominant. The protective effect of the cell wall immunodominant proteins was observed by immunizing BALB/c mice with cell wall protein extracts. After the immunization and booster, the BALC/c mice were challenged with a lethal dose of C. parapsilosis. In vivo results demonstrated increased survival rates and lower fungal burden in vital organs in the immunized mice compared to the unimmunized mice, thereby confirming the immunogenic property of cell wall-associated proteins of C. parapsilosis. Therefore, these results advocated the potential of these cell wall proteins to act as biomarkers for the development of diagnostic assays and/or vaccines against infections caused by C. parapsilosis.

1. Introduction

Infections, as the result of fungal pathogens, have been on the increase globally in recent decades, often in the form of nosocomial infection among hospital patients with compromised immune systems often due to AIDS, surgery, or cancer treatment. Candida species are well-known opportunistic pathogens that cause nosocomial infection worldwide, and invasive Candida infection (candidiasis) is the most prevalent in the world [1]. Candidiasis often results in blood infection (candidemia), which has a high mortality rate of above 40% [1,2]. In recent decades, infections caused by non-candida species such as Candida glabrata, Candida parapsilosis, Candida tropicalis, and Candida krusei have become more prevalent [3].
C. parapsilosis has become the most common non-candida species in South Africa, where there is also an alarming prevalence of azole-resistant C. parapsilosis infection [4], which causes outbreaks of neonatal bloodstream infections in ICU [5]. The azole resistance in C. parapsilosis is associated with a Y132F substitution within the ERG11 gene [6]. Underweight neonates are known to be more likely infected by C. parapsilosis, where the risk factors consist of horizontal transmissions, such as contamination via medical devices or fluids, hands of health care workers, prosthetic devices, and catheters [7].
The cell wall of a fungal pathogen is a vital organelle providing cellular strength and protection from the environment, and also has important roles in pathogen–host interaction including attachment to host tissues, biofilm formation, invasion, host immune recognition, immune evasion, and proteolytic activities [8]. The components of the Candida cell wall consist mostly of polysaccharides such as mannan, β-glucan, and chitin [9]. Disruption of cell wall components such as loss of proper N-linked mannosylation in C. parapsilosis cell wall due to knockout of the OCH1 gene (that encodes for a Golgi-resident a 1,6-mannosyltransferase) has been shown to cause slower growth, a clumpy cell phenotype, abnormal morphogenesis, defects in cell wall composition, irregular porosity, lower fitness, reduced virulence, and stronger immune response from human peripheral blood mononuclear cells though it does not affect phagocytosis by macrophages [10].
Due to all above mentioned information, treatment of C. parapsilosis infection is difficult. However, a vaccine can be a suitable alternative solution and experts have been calling for vaccines against fungal pathogens [11,12]. Currently, there is still no licensed vaccine against fungal pathogens available [13]. The goal of the current pilot study is to characterize immunodominant cell wall proteins of C. parapsilosis and observe its protective effect, which will be helpful for developing potential diagnostic biomarkers and vaccine candidates.

2. Materials and Methods

2.1. Candida Species

Twelve C. parapsilosis strains were isolated from clinical settings and stored under −80 °C in the Department of Clinical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of the Witwatersrand. The samples were stored inside 100% glycerol stock. We revived them by dropping 10 µL of glycerol stock onto Sabouraud dextrose agar (SDA) plates and incubating the plates for 48 h under 37 °C. All the strains were handled following the laboratory SOPs to avoid any contamination and cross-contamination. For biosafety, the protocol was assessed and approved by the Institutional Biosafety Committee under the reference number 20210502Lab.

2.2. Antifungal Susceptibility Profiling

We calculated the minimum inhibitory concentration (MIC) and the minimum fungicidal concentration (MFC) of the twelve clinical strains of C. parapsilosis using Fluconazole (FLZ; Sigma-Aldrich, St. Louis, MO, USA), Amphotericin B (AmB; Sigma-Aldrich, USA), Nystatin (NYST; Sigma-Aldrich, USA), and Caspofungin (CAS; Sigma-Aldrich, USA). A broth microdilution assay was performed under the guidelines recommended in the standard M27 document (4th ed.) presented by the Clinical and Laboratory Standard Institute [14]. The stock solution of the prior mentioned drugs was prepared using dimethyl sulfoxide (DMSO; Merck, RSA) and the test concentration ranged from 1250 to 9.77 µg/mL for FLZ, 62.5 to 0.49 µg/mL for AmB, 250 to 19.5 µg/mL for NYST, and 8 to 0.06 µg/mL for CAS. Sterility and growth control were included for comparison. The plates were incubated at 37 °C for 48 h. The MIC results were determined by visual observation, where antifungal drugs with the lowest concentration inhibited the fungal growth when compared to the growth control was considered as MIC value.
For estimating MFC, 10 µL from the wells with different concentrations of antifungal drugs were subcultured onto Sabouraud dextrose agar (SDA; Merck, RSA) plates followed by incubation at 37 °C for 48 h. The MFC was determined by observing the lowest concentration with no growth on the agar plate [15].

2.3. Extraction of Cell Wall Proteins

Cell wall proteins were extracted as described previously by El Khoury and co-workers with minor modifications [16]. C. parapsilosis MRU# 4112 was selected for cell wall protein extraction based on the antifungal susceptibility results. The concentration of C. parapsilosis MRU# 4112 cells was adjusted to 0.5 McFarland in 40 mL and was then inoculated in 2 L liquid mediums (2 to 100 mL ratio). The cells were incubated for 48 h in Sabouraud dextrose broth (SDB). Afterward, the cells were centrifuged at 4500 rpm for 3 min and were washed with PBS twice, resulting in an average of 7 g/L of C. parapsilosis cell pellet. Later on, the pellet was resuspended in 5 mL Tris (5 mM pH 7.8). A protease inhibitor cocktail (6 µL; Sigma-Aldrich, USA) was added along with glass beads (0.45–0.55 µm, Sigma-Aldrich, USA) at a 1:1 ratio to the pellet and vortexed for 10 cycles with 1 min on vortex followed by 1 min on ice. Thereafter, beads were removed by transferring the solution into another pre-weighed falcon tube. The remaining beads were washed several times with cold NaCl (1 mM) until the supernatant becomes transparent and mixed again in the respective falcon tubes without transferring any beads during the procedure. The samples were spun at 3000 rpm for 5 min and the supernatant was discarded and the pellet was resuspended in 40 mL 1M NaCl solution and spun at 3000 rpm for 5 min, repeated 3 to 4 times. Later on, protein extraction buffer (50 mM Tris; 2% SDS; 100 mM Na-EDTA; 150 mM NaCl; pH, 7.8) with beta-mercaptoethanol (β-ME), 8 µL per 1 mL PEB, was used to resuspend the washed pellet, 0.5 mL per 100 mg net weight cellular pellet followed by boiling for 10 min. The mixture was spun for 5 min at 3000 rpm; thereafter, the supernatants containing SDS extractables were collected. This procedure was performed twice. Acetone, at a 1:1 ratio to the supernatant, was added to the sample and incubated overnight under −20 °C. The next day, the samples were centrifuged at 4400 rpm for 5 min and the supernatant was poured out. The pellets were washed three times with acetone and left to dry. To determine the protein concentration, the dried protein powder was resuspended in protein lysis buffer [urea, 7 M; thiourea, 2 M; CHAPS, 4 % (w/v); pharmalyte, 0.8 % (v/v) (Thermo Fisher Scientific, Waltham, MA, USA)] and protein concentration was estimated using a DC Protein Assay (Bio-Rad), with BSA as a standard.

2.4. Sample Preparation for LC–MS Analysis

Cell wall extract samples were incubated with Bolt™ LDS sample buffer and sample reducing agent (Invitrogen, Waltham, MA, USA) and electrophoresed on a Bolt™ 4 to 12%, Bis-Tris, 1.0 mm, Mini Protein Gel (Invitrogen, USA). The polyacrylamide gels were stained with GelCode™ Blue Stain Reagent (Thermo Fisher Scientific, USA) and de-stained with Milli-Q water. Proteins were digested from gel fractions according to 1. Each sample was prepared in 6 separate gel fractions (based on approximated molecular weight ranges: >100, 60–100, 40–60, 25–40, 15–25, and <15 kDa). Briefly, the proteins were reduced in gel with 10 mM DTT in 25 mM AMBIC for 1 h at sixty degrees. Samples were cooled to room temperature, then 100% acetonitrile was added and incubated for 10 min. The supernatant was discarded and 55 mM iodoacetamide (IAA) in 25 mM AMBIC was added to the gel pieces. The reaction proceeded in the dark for 20 min at room temperature. The supernatant was discarded, and gels were dehydrated with 25 mM AMBIC in 50% acetonitrile, vortexed and the supernatant was removed. The gel pieces were dried to completeness and freshly prepared trypsin was added; protein digestion was allowed to proceed overnight at 37 °C. The digestion was quenched by adding formic acid to a final of 0.1% and the samples were dried under a vacuum. Dried samples were re-suspended in 2% acetonitrile and 0.2% formic acid for mass spectrometry analysis.

2.5. LC–MS Data Acquisition

Tryptic peptides from each gel fraction were analyzed using a Dionex Ultimate 3000 RSLC system coupled to an AB Sciex 6600 TripleTOF mass spectrometer. Injected peptides were inline de-salted using an Acclaim PepMap C18 trap column (75 μm × 2 cm; 2 min at 5 μL·min 1 using 2% ACN/0.2% FA). Trapped peptides were gradient eluted and separated on a Waters nanoEase CSH C18 column (75 μm × 25 cm, 1.7 µm particle size) at a flow rate of 0.3 µL·min 1 with a gradient of 10–55% B over 10 min (A: 0.1% FA; B: 80% ACN/0.1% FA). The 6600 TripleTOF mass spectrometer was operated in the positive ion mode. Data-dependent acquisition (DDA) was employed; precursor (MS) scans were acquired from m/z 400 to 1500 (2+–5+ charge states) using an accumulation time of 100 ms followed by 40 fragment ion (MS/MS) scans, acquired from m/z 100 to 1800 with 20 ms accumulation time each.

2.6. LC–MS Database Searching

Raw data files (.wiff) were searched with Protein Pilot V5.0 software (SCIEX), using a database containing sequences from C. parapsilosis reference proteome (downloaded from UniProt on 24 June 2021) and common contaminants. Trypsin was set as the digestion enzyme, cysteine alkylation (iodoacetamide) was allowed as a fixed modification and biological modifications were allowed in the search parameters. A 1% false discovery rate filter was applied at the protein level for the refinement of identifications.

2.7. Bioinformatic and Functional Analyses

The list of gene names for the identified proteins was used to obtain the protein sequences (ORF translation) from the Candida Genome Database (http://www.candidagenome.org/, accessed 13 December 2022) 2 using the CGD Batch Download tool and gene ontology enrichment analysis performed using the CGD GO Slim Mapper tool using the default settings. The complete list of sequences was submitted to the VaxiJen v2.0 server (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) 3 to predict the presence of protective antigens, a threshold score of 0.9 was applied. The DeepLoc-1.0 (https://services.healthtech.dtu.dk/service.php?DeepLoc-1.0) 4 server was used to accurately (profile setting) predict subcellular localization of the predicted antigens.

2.8. In Vivo Study

BALB/c mice, 8 to 10 weeks old, were used for this study. The mice were acclimatized for a week and weighted weekly (18–21 g). All animal studies were performed according to the protocol for the care and use of animals sanctioned by the Animal Research Ethics Committee (AREC), University of the Witwatersrand, Johannesburg, South Africa (AREC- 2022/01/01/C). The protocol was inspected and approved by the Institutional Biosafety Committee (IBC) and the Department of Agriculture, Land Reform and Rural Development (DALRRD).

2.9. Immunization

A total of 36 BALB/c mice were used in the animal model. The mice were randomly separated into 3 groups: (a) the healthy control group (n = 12), (b) the infection control group (n = 12), and (c) the immunization group (n = 12). The control group was mock immunized with 0.2 mL of sterile phosphate buffer saline whereas, in order to ensure the injection of a sufficient quantity of protein extract that may induce an appropriate immune response against C. parapsilosis infection, the test groups were injected with 300 µg of cell wall protein extract via the intraperitoneal route [17]. However, the protein extract was not supported with any adjuvant system. Thereafter, a booster dose of the same protein concentration was given on day 21. Afterward, all the mice, except the healthy control group, were infected with a lethal injection of C. parapsilosis MRU# 4112 (5 × 106 CFU/mL) (as estimated by using MicroScan Turbidity meter, Beckman Coulter, in a total volume of 150 μL of sterile saline) via the intravenous route. Plate counts were performed for confirmation of the cell count and viability of infecting inoculum in each mouse. The protective effect was observed for 3 weeks after the infection by monitoring the survival rate of mice in the vaccinated group.

2.10. Histopathology

After observing the protective effect for 3 weeks, all the mice were sacrificed according to the SOP followed by the Wits Research Animal Facility. After the euthanization of mice, kidneys, lungs, livers, and spleens were removed aseptically and weighed. The collected organs were then fixed and stored in 10% buffered formalin. The fixed tissues were embedded in paraffin followed by cutting a longitudinal section of 4 µm and stained with Periodic acid-Schiff (PAS). The stained sections were then observed under a microscope (Leica Microsystems, Heerbrugg, Switzerland).
The images of the samples were taken under a lens of 100× magnification. Day light blue filter was used to balance out the color of the light source. LED was used as the light source. Color corrections were performed for images that were too yellow or blue.
The collected organs were homogenized in sterile PBS (chilled) and the processed homogenate was then seeded onto SDA plates containing 100 µg/mL ampicillin. The plates were incubated at 37 °C for 48 h and afterward, colonies were counted, and the result was recorded as log10 CFU/mg of tissue for estimating the fungal burden.

2.11. Statistical Analysis

The results of fungal burden were analyzed using a log-rank test and the unpaired Student’s t-test (two tailed) in GraphPad Prism software, version 8.0.1. Statically significant differences were defined as p-value.

3. Results

3.1. Antifungal Susceptibility Profiling

Antifungal susceptibility profiling of the twelve C. parapsilosis strains was performed against four commonly used antifungal drugs under the CLSI-recommended guidelines. The results obtained from the broth microdilution assay, MIC, and MFC values for FLZ, AmB, NYST, and CAS were recorded in Table 1. According to the MIC and MFC results, C. parapsilosis MRU# 4112 was selected for further analysis.

3.2. Proteomic Analysis of the Cell Wall-Associated Proteins and Protective Antigen Prediction

Liquid chromatography–mass spectrometry (LC–MS) identified 933 protein groups for cell wall extract of C. parapsilosis MRU# 4112 strain. Gene set-enrichment analysis showed a high frequency of proteins involved in the regulation of biological processes (194 proteins, 20.8%), transport (182 proteins, 19.5%), and organelle organization (168 proteins, 18%). The enrichment distribution of all identified proteins in the cell wall extract is shown in Figure 1. Other significant biological processes that were observed at a low frequency are cell adhesion (3 proteins: protein transport protein SEC31, agglutinin-like protein 7, and non-specific serine/threonine protein kinase), biofilm formation (3 proteins: non-specific serine/threonine protein kinase, fatty acid synthase subunit alpha, and HTH APSES-type domain-containing protein) and response to drugs (2 proteins: E3 ubiquitin-protein ligase and CRAL-TRIO domain-containing protein).

3.3. Functional Analysis of Predicted Antigens of C. parapsilosis MRU# 4112 Strain Cell Wall Extract

Thirty-four of the identified proteins were predicted to be protective antigens (Table 2). The predicted antigens were further annotated by determining the subcellular localization using the DeepLoc 4 prediction tool. Five antigenic proteins were predicted to occur in the membrane form or localized to the extracellular space: Candida ALS N domain-containing protein and four uncharacterized proteins. Wewe collated the C. albicans orthologs of each of these antigenic proteins to provide further functional annotation (Table 3). However, three of the ortholog proteins are also uncharacterized in C. albicans strains.

3.4. In Vivo Studies

Effectiveness of Immunization

The lethal dose of C. parapsilosis challenge (5 × 106 CFU/mL) did not induce 100% mortality in the infection control group. However, mice in the infection control group displayed signs of distress such as orbital tightening, rough hair coat, and gradual weight loss after 48 and 72 h of infection, which was used as a sign of morbidity that depends on both fungal virulence and the host’s inflammatory immune response. Several studies have used this marker for disease severity in mice with invasive candidiasis or other types of infection [18,19,20,21]. According to the protocol, we had to sacrifice the mice when such signs of distress appear. These results are similar to another study for analyzing the protective effect of C. parapsilosis cell wall mutant [10]. Mice (n = 4) from the healthy control, infection control, and immunization group were sacrificed after 48 and 72 h of infection to further investigate the protective effects of cell wall proteins, while the remaining mice were observed until the end of the experiment (21 days) (Figure 2). According to plate count, the CFU on the plates for the immunization group was significantly lower than the infection control group (Figure 3).

3.5. Histopathology

A higher C. parapsilosis cell distribution can be observed in the liver, lungs, and spleen tissue sections of the infection control mouse, while damaged tissues can be observed in the kidneys. Whereas significantly less fungal burden was observed in the mouse immunized with cell wall protein. The C. parapsilosis was presented only in the yeast form and this finding was in agreement with previous studies [21,22] Therefore, the results advocated the protective effect of the cell wall proteins against C. parapsilosis infection (Figure 4).

4. Discussion

C. parapsilosis has developed a trend of increasing antifungal drug resistance in recent years. Therefore, it has become paramount to develop a vaccine for protection against infection. However, there is currently no available vaccine against fungal infection. In this study, we extracted C. parapsilosis MRU# 4112 cell wall protein and injected it into BALB/c mice to prevent C. parapsilosis infection.
According to the functional analysis, 933 proteins were found, and 34 out of 933 proteins were predicted to be antigenic. Five of the identified antigenic proteins were identified as membrane or extracellular proteins (bold font). However, four out of the five were uncharacterized proteins (Table 1). The only characterized protein is located on the cell membrane, CPAR2_404800, which encodes Candida ALS N domain-containing protein.
The CPAR2_404800 gene is homologic to ALS7/C3_06320W_A in C. albicans SC5314, which encodes the C. albicans ALS7 protein. The agglutinin-like sequence (ALS) family protein consists of eight discovered genes that encode large glycosylphosphatidylinositol (GPI)-linked glycoproteins on the cell surface and is well known to play an important role in adhesion to the host cells in C. albicans [23] and Saccharomyces cerevisiae [24], which is vital for pathogenesis as adhesion toward human epithelial cells can significantly increase the risk of invasive Candidiasis. The ability of adherence to biotic and/or abiotic surfaces is also an important function of the cell wall proteins, which allows the fungus to colonize the host and/or medical devices. The disruption of this gene in C. parapsilosis can result in a reduction in adhesion and virulence [25]. The C. parapsilosis ALS7 protein has a strong capacity for binding to plasminogen and high-molecular-mass kininogen, which are essential components of the human fibrinolytic system and proinflammatory/procoagulant contact-activated kinin-forming system, respectively [26]. The disruption of these two systems can result in the development of systemic inflammatory response syndrome (SIRS), septic shock, and severe sepsis often associated with critical conditions and death [27,28].
The other four proteins, namely CPAR2_405130, CPAR2_701270, CPAR2_703940, and CPAR2_805040, were uncharacterized in C. parapsilosis. All these uncharacterized proteins were discovered a long time ago, but not much follow-up research performed in the Candida species, especially C. parapsilosis. Now that we have predicted that these proteins can play important role in raising host immune response against C. parapsilosis, more research should be conducted to further investigate the immunomodulatory aspect of these proteins.
CPAR2_405130 is homologic to C. albicans C3_02270W; however, its function is uncharacterized among the Candida species. Its gene ortholog is SPAC26A3.14c in Schizosaccharomyces pombe, which is a hypothetical protein with a low UV sensitivity [29,30].
CPAR2_701270 is orthologous to C. albicans PHO88/CR_09320C and C. glabrata PHO88/CAGL0K12276g. PHO88/CR_09320C is a C. albicans membrane proteome that plays roles in phosphate transportation and biofilm-regulated expression, while Amphotericin B can repress its function [31,32,33]. Although PHO88/CAGL0K12276g was discovered in C. glabrata with high similarity to Saccharomyces cerevisiae, its function is assumed to be involved in the PHO signal pathway during phosphate starvation, similar to the one in S. cerevisiae [34].
CPAR2_703940 is orthologous Saccharomyces cerevisiae PRB1 to C. albicans C7_03860W and C. glabrata CAGL0B03619g. In S. cerevisiae PRB1 is the gene that encodes the precursor of a vacuolar protease that functions as a proteinase that degrades and overturns proteins during limiting nutrient and stressful conditions [35,36,37,38]. The gene is repressed by glucose, indicating PRB1 expression is activated when an alternative source of carbon is needed for synthesizing ATP [39]. The PRB1 gene is also required for Histone H3 N terminal truncation in yeast cells [40]. The ortholog C7_03860W was characterized in C. albicans as a vacuolar protease [41]. The gene is expressed when C. albicans encounter polymorphonuclear leukocytes such as neutrophils, possibly due to downregulating of C. albicans protein synthesis and reduced proliferation as a result of a lack of nutrients [42]. The ortholog CAGL0B03619g is expressed in C. glabrata during osmotic stress [43]. In both cases, the orthologs have a similar function to the PRB1 in S. cerevisiae.
CPAR2_805040 is characterized as a secretory protein located in C. parapsilosis cell wall with an unknown function [44]. The alias of the gene, CPAG_03284, has an increased expression in azole-resistant C. parapsilosis strains [45]. The gene is orthologous to C. albicans C1_10170W, which was discovered during an antifungal compound experiment [46]. However, the function of this C. albicans extracellular secretome is currently unknown [47].
Furthermore, proteins such as CPAR2_405130, 701270, 703940, and 805040 found in the protein extracts were characterized as moonlight proteins. Notably, moonlight proteins have more than one function in Candida species; although they originated in the cytoplasm, they can be found in cell walls with a different purpose and plays a vital role in the pathogenicity of Candida species. Studies have shown these moonlight proteins have the potential to be used as a vaccine against C. albicans and C. glabrata infection [48].
The orthologous of the protein encoded by CPAR2_404800, CPAR2_701270, CPAR2_703940, and CPAR2_805040 are mostly reported for one or the other pathogenic attributes in different species Candida and S. cerevisiae and therefore, the presence of these virulence-associated proteins in cell wall extract of C. parapsilosis further advocate its immunogenic property. Moreover, we speculate that these proteins are immunogenic in nature and together they might have the potency to trigger a strong immune response against the C. parapsilosis in the vaccinated group. Most importantly, the antigens from the cell wall proteins of Candida species have the ability to activate the adaptive immune response including Th1 (type 1 helper T-cell) and Th17 cell immune responses, antigen presenting cells (APCs), B cells and T cells during infection to reduce fungal burden [48,49,50,51,52,53]. The APCs (such as macrophages and dendritic cells) when come in contact with the cell wall proteins release cytokines IFN-γ and IL-2 to activate Th1 response, which in turn leads to macrophages activation to release IFN-γ and IL-12 to activate more macrophages and Th1 [51]. Additionally, the cell wall proteins also stimulate Th17 differentiation which releases IL-17 to prolong the survival of neutrophils and activate and recruit neutrophils to the infection site to engulf Candida cells and induce inflammation [51]. The APCs also present cell wall antigens to the CD4+ T cells and CD8+ T cells, the CD4+ T cells then present to the B cells to develop into plasma cells and create antibodies [52,53]. Alternatively, it is also possible that the immune response mostly involved the components of the innate immune system. Where myeloid cells including peripheral blood mononuclear cells, peripheral blood mononuclear cell-derived macrophages, polymorphonuclear neutrophils, DCs, and bone marrow-derived macrophages all involved in the innate immune response against C. parapsilosis infection; which are triggered by the non-protein components of C. parapsilosis cell walls [54]. Correspondingly, the C. parapsilosis infection activates the peripheral blood mononuclear cells to release pro-inflammatory cytokines including IL-1β, IL-6, and tumor necrosis factor alpha, as well as anti-inflammatory cytokines IL-10 and eliminate fungal yeast cells via phagocytosis. Moreover, due to a lack of research and published data in C. parapsilosis, we conjectured that these proteins together might play important role in activating host immune response in a similar manner as observed in other Candida species. The cell wall protein extract appeared to protect BALB/c mice from C. parapsilosis infection which was further supported by the histopathology results (Figure 4). In another study, Pérez-García et al. (2016) [10] using an animal model found that BALB/c mice infected by C. parapsilosis och1Δ null mutant had a significant reduction in fungal burden in the spleen, kidneys, and liver at 1, 2, and 7 days post infection comparing to WT C. parapsilosis, which is very similar to our results of using cell wall proteins to protect mice against infection. Furthermore, in the kidneys, we did not see individual C. parapsilosis cells as clearly as in the other organs; however, we do see the damages caused by the infection were mild in the immunized mice as compared to the infection control group. In all other organs (the spleen, liver, and lung), scattered individual cells can be observed in the immunized mouse. Where significantly more cells and even clusters of C. parapsilosis cells can be observed in the infection control mouse. We can see that the C. parapsilosis cells infected the periphery of the lungs). We have also used VITEK 2 System version 9.02 to identify the colonies that grew on the plates for fungal burden analysis. The result indicates that the colonies were C. parapsilosis (Supplementary File S1).

5. Conclusions

The pilot study has successfully shown that the antigens from extracted cell wall proteins of C. parapsilosis MRU# 4112 can be identified using mass spectrometry and the immunodominant proteins can protect mice from infections. A total of 34 immunodominant proteins were identified, including CPAR2_405130, CPAR2_701270, CPAR2_703940, and CPAR2_805040, which are new immunodominant proteins that have not been characterized in C. parapsilosis yet. A few were characterized in C. albicans that function in stress response, resistance, and pathogenicity pathways (CPAR2_404800, CPAR2_701270, and CPAR2_703940). It is hypothesized that the cell wall proteins induced antibodies in mice, which prevented disseminated Candida infection. The results have showed that the characterized immunodominant proteins have the potential to be used as diagnostic biomarkers and vaccines against C. parapsilosis infection. However, more studies need to be conducted such as purification of these immunodominant proteins and applied to in vivo models to identify and evaluate the protective potential of individual proteins against different Candida infections.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines11030674/s1, Supplementary File S1: Result of VITEK 2 analysis for the colonies after CFU plate counting confirming C. parapsilosis cells.

Author Contributions

Conceptualization, A.K. and A.A.; methodology, X.G., V.S. and P.N.; software, X.G., V.S. and P.N.; validation, X.G., A.K. and P.N.; formal analysis, V.S., A.K. and P.N.; investigation, A.K. and A.A.; resources, A.A.; data curation, X.G., P.N.; writing—original draft preparation, X.G., P.N.; writing—review and editing, V.S., A.K. and A.A.; visualization, A.A. and V.S.; supervision, A.A. and A.K.; project administration, A.A.; funding acquisition, A.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by a South African National Research Foundation (NRF) Research Development Grant for Y-Rated Researchers (RDYR180418322304; Grant No: 116339), and a University Research Committee Grant for 2019-Friedel Sellschop Award (Grant No: AZMD019).

Institutional Review Board Statement

All animal studies were performed according to the protocol for the care and use of animals sanctioned by the Animal Research Ethics Committee (AREC), University of the Witwatersrand, Johannesburg, South Africa (AREC- 2022/01/01/C). The protocol was inspected and approved by the Institutional Biosafety Committee (IBC) and the Department of Agriculture, Land Reform and Rural Development (DALRRD).

Informed Consent Statement

Not applicable.

Data Availability Statement

The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bongomin, F.; Gago, S.; Oladele, R.O.; Denning, D.W. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J. Fungi 2017, 3, 57. [Google Scholar] [CrossRef] [PubMed]
  2. Wisplinghoff, H.; Bischoff, T.; Tallent, S.M.; Seifert, H.; Wenzel, R.P.; Edmond, M.B. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 2004, 39, 309–317. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Whaley, S.G.; Berkow, E.L.; Rybak, J.M.; Nishimoto, A.T.; Barker, K.S.; Rogers, P.D. Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Front. Microbiol. 2016, 7, 2173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Govender, N.P.; Patel, J.; Magobo, R.E.; Naicker, S.; Wadula, J.; Whitelaw, A.; Coovadia, Y.; Kularatne, R.; Govind, C.; Lockhart, S.R.; et al. Emergence of azole-resistant Candida parapsilosis causing bloodstream infection: Results from laboratory-based sentinel surveillance in South Africa. J. Antimicrob. Chemother. 2016, 71, 1994–2004. [Google Scholar] [CrossRef] [Green Version]
  5. Magobo, R.E.; Naicker, S.D.; Wadula, J.; Nchabeleng, M.; Coovadia, Y.; Hoosen, A.; Lockhart, S.R.; Govender, N.P.; the TRAC-South Africa Group. Detection of neonatal unit clusters of Candida parapsilosis fungaemia by microsatellite genotyping: Results from laboratory-based sentinel surveillance, South Africa, 2009–2010. Mycoses 2017, 60, 320–327. [Google Scholar] [CrossRef]
  6. Magobo, R.E.; Lockhart, S.R.; Govender, N.P. Fluconazole-resistant Candida parapsilosis strains with a Y132F substitution in the ERG11 gene causing invasive infections in a neonatal unit, South Africa. Mycoses 2020, 63, 471–477. [Google Scholar] [CrossRef]
  7. Trofa, D.; Gacser, A.; Nosanchuk, J.D. Candida parapsilosis, an emerging fungal pathogen. Clin. Microbiol. Rev. 2008, 21, 606–625. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Gow, N.A.; van de Veerdonk, F.L.; Brown, A.J.; Netea, M.G. Candida albicans morphogenesis and host defence: Discriminating invasion from colonization. Nat. Rev. Microbiol. 2011, 10, 112–122. [Google Scholar] [CrossRef] [Green Version]
  9. Free, S.J. Fungal cell wall organization and biosynthesis. Adv. Genet. 2013, 81, 33–82. [Google Scholar] [CrossRef]
  10. Perez-Garcia, L.A.; Csonka, K.; Flores-Carreon, A.; Estrada-Mata, E.; Mellado-Mojica, E.; Nemeth, T.; Lopez-Ramirez, L.A.; Toth, R.; Lopez, M.G.; Vizler, C.; et al. Role of Protein Glycosylation in Candida parapsilosis Cell Wall Integrity and Host Interaction. Front Microbiol 2016, 7, 306. [Google Scholar] [CrossRef] [Green Version]
  11. Nanjappa, S.G.; Klein, B.S. Vaccine immunity against fungal infections. Curr. Opin. Immunol. 2014, 28, 27–33. [Google Scholar] [CrossRef] [Green Version]
  12. Piccione, D.; Mirabelli, S.; Minto, N.; Bouklas, T. Difficult but not impossible: In Search of an anti-Candida Vaccine. Curr. Trop. Med. Rep. 2019, 6, 42–49. [Google Scholar] [CrossRef] [Green Version]
  13. Ahmadipour, S.; Field, R.A.; Miller, G.J. Prospects for anti-Candida therapy through targeting the cell wall: A mini-review. Cell Surf. 2021, 7, 100063. [Google Scholar] [CrossRef] [PubMed]
  14. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 4th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2017. [Google Scholar]
  15. Srivastava, V.; Ahmad, A. Abrogation of pathogenic attributes in drug resistant Candida auris strains by farnesol. PLoS ONE 2020, 15, e0233102. [Google Scholar] [CrossRef]
  16. El Khoury, P.; Awad, A.; Wex, B.; Khalaf, R.A. Proteomic analysis of a Candida albicans pir32 null strain reveals proteins involved in adhesion, filamentation and virulence. PLoS ONE 2018, 13, e0194403. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Singh, S.; Uppuluri, P.; Mamouei, Z.; Alqarihi, A.; Elhassan, H.; French, S.; Lockhart, S.R.; Chiller, T.; Edwards, J.E., Jr.; Ibra-him, A.S. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. PLOS Pathog. 2019, 15, e1007460. [Google Scholar] [CrossRef] [Green Version]
  18. Arendrup, M.; Horn, T.; Frimodt-Møller, N. In Vivo Pathogenicity of Eight Medically Relevant Candida Species in an Animal Model. Infection 2002, 30, 286–291. [Google Scholar] [CrossRef] [PubMed]
  19. Spellberg, B.; Ibrahim, A.S.; Edwards, J.E., Jr.; Filler, S.G. Mice with disseminated candidiasis die of progressive sepsis. J. Infect. Dis. 2005, 192, 336–343. [Google Scholar] [CrossRef]
  20. Trammell, R.A.; Toth, L.A. Markers for predicting death as an outcome for mice used in infectious disease research. Comp. Med. 2011, 61, 492–498. Available online: http://aalas.publisher.ingentaconnect.com/content/aalas/cm/2011/00000061/00000006/art00002# (accessed on 20 February 2023). [PubMed]
  21. Dimopoulou, D.; Hamilos, G.; Tzardi, M.; Lewis, R.E.; Samonis, G.; Kontoyiannis, D.P. Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility. Antimicrob. Agents Chemother. 2014, 58, 229–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Hirayama, T.; Miyazaki, T.; Ito, Y.; Wakayama, M.; Shibuya, K.; Yamashita, K.; Takazono, T.; Saijo, T.; Shimamura, S.; Yamamoto, K.; et al. Virulence assessment of six major pathogenic Candida species in the mouse model of invasive candidiasis caused by fungal translocation. Sci. Rep. 2020, 10, 3814. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Hoyer, L.L.; Green, C.B.; Oh, S.H.; Zhao, X. Discovering the secrets of the Candida albicans agglutinin-like sequence (ALS) gene family—A sticky pursuit. Med. Mycol. 2008, 46, 1–15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Neale, M.N.; Glass, K.A.; Longley, S.J.; Kim, D.J.; Laforce-Nesbitt, S.S.; Wortzel, J.D.; Shaw, S.K.; Bliss, J.M. Role of the Inducible Adhesin CpAls7 in Binding of Candida parapsilosis to the Extracellular Matrix under Fluid Shear. Infect. Immun. 2018, 86, e00892-17. [Google Scholar] [CrossRef] [Green Version]
  25. Bertini, A.; Zoppo, M.; Lombardi, L.; Rizzato, C.; De Carolis, E.; Vella, A.; Torelli, R.; Sanguinetti, M.; Tavanti, A. Targeted gene disruption in Candida parapsilosis demonstrates a role for CPAR2_404800 in adhesion to a biotic surface and in a murine model of ascending urinary tract infection. Virulence 2016, 7, 85–97. [Google Scholar] [CrossRef] [Green Version]
  26. Karkowska-Kuleta, J.; Zajac, D.; Bras, G.; Bochenska, O.; Rapala-Kozik, M.; Kozik, A. Binding of human plasminogen and high-molecular-mass kininogen by cell surface-exposed proteins of Candida parapsilosis. Acta Biochim. Pol. 2017, 64, 391–400. [Google Scholar] [CrossRef]
  27. Duggan, S.; Leonhardt, I.; Hunniger, K.; Kurzai, O. Host response to Candida albicans bloodstream infection and sepsis. Virulence 2015, 6, 316–326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Ng, K.; Schorr, C.; Reboli, A.C.; Zanotti, S.; Tsigrelis, C. Incidence and mortality of sepsis, severe sepsis, and septic shock in intensive care unit patients with candidemia. Infect. Dis. 2015, 47, 584–587. [Google Scholar] [CrossRef]
  29. Lepingle, A.; Casaregola, S.; Neuveglise, C.; Bon, E.; Nguyen, H.; Artiguenave, F.; Wincker, P.; Gaillardin, C. Genomic exploration of the hemiascomycetous yeasts: 14. Debaryomyces hansenii var. hansenii. FEBS Lett. 2000, 487, 82–86. [Google Scholar] [CrossRef] [Green Version]
  30. Rooney, J.P.; Patil, A.; Joseph, F.; Endres, L.; Begley, U.; Zappala, M.R.; Cunningham, R.P.; Begley, T.J. Cross-species Functionome analysis identifies proteins associated with DNA repair, translation and aerobic respiration as conserved modulators of UV-toxicity. Genomics 2011, 97, 133–147. [Google Scholar] [CrossRef] [Green Version]
  31. Garcia-Sanchez, S.; Aubert, S.; Iraqui, I.; Janbon, G.; Ghigo, J.M.; d’Enfert, C. Candida albicans biofilms: A developmental state associated with specific and stable gene expression patterns. Eukaryot. Cell 2004, 3, 536–545. [Google Scholar] [CrossRef] [Green Version]
  32. Liu, T.T.; Lee, R.E.; Barker, K.S.; Lee, R.E.; Wei, L.; Homayouni, R.; Rogers, P.D. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob. Agents Chemother. 2005, 49, 2226–2236. [Google Scholar] [CrossRef] [Green Version]
  33. Cabezon, V.; Llama-Palacios, A.; Nombela, C.; Monteoliva, L.; Gil, C. Analysis of Candida albicans plasma membrane proteome. Proteomics 2009, 9, 4770–4786. [Google Scholar] [CrossRef] [PubMed]
  34. Kerwin, C.L.; Wykoff, D.D. Candida glabrata PHO4 is necessary and sufficient for Pho2-independent transcription of phosphate starvation genes. Genetics 2009, 182, 471–479. [Google Scholar] [CrossRef] [Green Version]
  35. Teichert, U.; Mechler, B.; Muller, H.; Wolf, D.H. Lysosomal (vacuolar) proteinases of yeast are essential catalysts for protein degradation, differentiation, and cell survival. J. Biol. Chem. 1989, 264, 16037–16045. [Google Scholar] [CrossRef]
  36. Zubenko, G.S.; Jones, E.W. Protein degradation, meiosis and sporulation in proteinase-deficient mutants of Saccharomyces cerevisiae. Genetics 1981, 97, 45–64. [Google Scholar] [CrossRef]
  37. Hecht, K.A.; O’Donnell, A.F.; Brodsky, J.L. The proteolytic landscape of the yeast vacuole. Cell. Logist. 2014, 4, e28023. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Gil-Bona, A.; Parra-Giraldo, C.M.; Hernaez, M.L.; Reales-Calderon, J.A.; Solis, N.V.; Filler, S.G.; Monteoliva, L.; Gil, C. Candida albicans cell shaving uncovers new proteins involved in cell wall integrity, yeast to hypha transition, stress response and host-pathogen interaction. J. Proteom. 2015, 127, 340–351. [Google Scholar] [CrossRef] [Green Version]
  39. Naik, R.R.; Nebes, V.; Jones, E.W. Regulation of the proteinase B structural gene PRB1 in Saccharomyces cerevisiae. J. Bacteriol. 1997, 179, 1469–1474. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Xue, Y.; Vashisht, A.A.; Tan, Y.; Su, T.; Wohlschlegel, J.A. PRB1 is required for clipping of the histone H3 N terminal tail in Saccharomyces cerevisiae. PLoS ONE 2014, 9, e90496. [Google Scholar] [CrossRef] [Green Version]
  41. Monteoliva, L.; Matas, M.L.; Gil, C.; Nombela, C.; Pla, J. Large-scale identification of putative exported proteins in Candida albicans by genetic selection. Eukaryot. Cell 2002, 1, 514–525. [Google Scholar] [CrossRef] [Green Version]
  42. Fradin, C.; De Groot, P.; MacCallum, D.; Schaller, M.; Klis, F.; Odds, F.C.; Hube, B. Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood. Mol. Microbiol. 2005, 56, 397–415. [Google Scholar] [CrossRef]
  43. Roetzer, A.; Gregori, C.; Jennings, A.M.; Quintin, J.; Ferrandon, D.; Butler, G.; Kuchler, K.; Ammerer, G.; Schuller, C. Candida glabrata environmental stress response involves Saccharomyces cerevisiae Msn2/4 orthologous transcription factors. Mol. Microbiol. 2008, 69, 603–620. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Moreno-Martinez, A.E.; Gomez-Molero, E.; Sanchez-Virosta, P.; Dekker, H.L.; de Boer, A.; Eraso, E.; Bader, O.; de Groot, P.W.J. High Biofilm Formation of Non-Smooth Candida parapsilosis Correlates with Increased Incorporation of GPI-Modified Wall Adhesins. Pathogens 2021, 10, 493. [Google Scholar] [CrossRef] [PubMed]
  45. Silva, A.P.; Miranda, I.M.; Guida, A.; Synnott, J.; Rocha, R.; Silva, R.; Amorim, A.; Pina-Vaz, C.; Butler, G.; Rodrigues, A.G. Transcriptional profiling of azole-resistant Candida parapsilosis strains. Antimicrob. Agents Chemother. 2011, 55, 3546–3556. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Neuhof, T.; Seibold, M.; Thewes, S.; Laue, M.; Han, C.O.; Hube, B.; von Dohren, H. Comparison of susceptibility and transcription profile of the new antifungal hassallidin A with caspofungin. Biochem. Biophys. Res. Commun. 2006, 349, 740–749. [Google Scholar] [CrossRef] [PubMed]
  47. Gil-Bona, A.; Monteoliva, L.; Gil, C. Global Proteomic Profiling of the Secretome of Candida albicans ecm33 Cell Wall Mutant Reveals the Involvement of Ecm33 in Sap2 Secretion. J. Proteome Res. 2015, 14, 4270–4281. [Google Scholar] [CrossRef]
  48. Medrano-Diaz, C.L.; Vega-Gonzalez, A.; Ruiz-Baca, E.; Moreno, A.; Cuellar-Cruz, M. Moonlighting proteins induce protection in a mouse model against Candida species. Microb. Pathog. 2018, 124, 21–29. [Google Scholar] [CrossRef]
  49. Shen, H.; Yu, Y.; Chen, S.M.; Sun, J.J.; Fang, W.; Guo, S.Y.; Hou, W.T.; Qiu, X.R.; Zhang, Y.; Chen, Y.L.; et al. Dectin-1 Facilitates IL-18 Production for the Generation of Protective Antibodies Against Candida albicans. Front. Microbiol. 2020, 11, 1648. [Google Scholar] [CrossRef]
  50. Nami, S.; Mohammadi, R.; Vakili, M.; Khezripour, K.; Mirzaei, H.; Morovati, H. Fungal vaccines, mechanism of actions and immunology: A comprehensive review. Biomed. Pharmacother. 2019, 109, 333–344. [Google Scholar] [CrossRef]
  51. Shi, H.; Dong, S.; Zhang, X.; Chen, X.; Gao, X.; Wang, L. Phage vaccines displaying YGKDVKDLFDYAQE epitope induce protection against systemic candidiasis in mouse model. Vaccine 2018, 36, 5717–5724. [Google Scholar] [CrossRef]
  52. Alqarihi, A.; Singh, S.; Edwards, J.E., Jr.; Ibrahim, A.S.; Uppuluri, P. NDV-3A vaccination prevents C. albicans colonization of jugular vein catheters in mice. Sci. Rep. 2019, 9, 6194. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Ibrahim, A.S.; Luo, G.; Gebremariam, T.; Lee, H.; Schmidt, C.S.; Hennessey, J.P., Jr.; French, S.W.; Yeaman, M.R.; Filler, S.G.; Edwards, J.E., Jr. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. Vaccine 2013, 31, 5549–5556. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Toth, R.; Nosek, J.; Mora-Montes, H.M.; Gabaldon, T.; Bliss, J.M.; Nosanchuk, J.D.; Turner, S.A.; Butler, G.; Vagvolgyi, C.; Gacser, A. Candida parapsilosis: From Genes to the Bedside. Clin. Microbiol. Rev. 2019, 32, e00111-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Vaccines 11 00674 g001 550
Figure 1. Bar graph showing gene ontology enrichment analysis of biological processes for the proteins identified in the cell wall extract. Biological processes that were common to <5% of the proteins were excluded from the chart.
Figure 1. Bar graph showing gene ontology enrichment analysis of biological processes for the proteins identified in the cell wall extract. Biological processes that were common to <5% of the proteins were excluded from the chart.
Vaccines 11 00674 g001
Vaccines 11 00674 g002 550
Figure 2. Survival probability of cell wall protein immunized BALB/c mice. The survival proportion states the potency of cell wall protein extract in protection against infection caused C. parapsilosis. Mantel–Cox log-range test was used to compare the survival in different groups. HC = health control; CWP = cell wall protein; IC = infection control. p value < 0.005.
Figure 2. Survival probability of cell wall protein immunized BALB/c mice. The survival proportion states the potency of cell wall protein extract in protection against infection caused C. parapsilosis. Mantel–Cox log-range test was used to compare the survival in different groups. HC = health control; CWP = cell wall protein; IC = infection control. p value < 0.005.
Vaccines 11 00674 g002
Vaccines 11 00674 g003 550
Figure 3. Analysis of fungal burden. The effect of cell wall protein extract against infection caused by C. parapsilosis. The fungal burden was expressed as geometric means of logarithmic values for CFU/mg of tissues. HC = health control; CWP = cell wall protein; IC = infection control. (*** p < 0.05).
Figure 3. Analysis of fungal burden. The effect of cell wall protein extract against infection caused by C. parapsilosis. The fungal burden was expressed as geometric means of logarithmic values for CFU/mg of tissues. HC = health control; CWP = cell wall protein; IC = infection control. (*** p < 0.05).
Vaccines 11 00674 g003
Vaccines 11 00674 g004 550
Figure 4. Comparative analysis of histopathology of different tissue sections from healthy control, immunized, and C. parapsilosis-infected mice after 48 h. Tissue sections recovered post infections were stained with PAS. The mouse from the infection control group displayed a higher fungal burden. While the cell wall protein immunized mouse showed significantly reduced fungal burden. The black arrows indicate of C. parapsilosis cells in the target tissues while the brown arrows indicate the damages in the kidney.
Figure 4. Comparative analysis of histopathology of different tissue sections from healthy control, immunized, and C. parapsilosis-infected mice after 48 h. Tissue sections recovered post infections were stained with PAS. The mouse from the infection control group displayed a higher fungal burden. While the cell wall protein immunized mouse showed significantly reduced fungal burden. The black arrows indicate of C. parapsilosis cells in the target tissues while the brown arrows indicate the damages in the kidney.
Vaccines 11 00674 g004
Table
Table 1. Antifungal susceptibility profiling.
Table 1. Antifungal susceptibility profiling.
Strain01IS MRU#: 431502IS MRU#: 428203IS MRU#: 409004IS MRU#: 4112
µg/mLMICMFCMICMFCMICMFCMICMFC
FLZ312.500FS625.000FS312.500FS312.500FS
AmB0.9771.9530.9771.9530.9771.95331.25062.500
NYST62.500125.00031.250FS62.500FS125.000FS
CAS0.1250.2500.1250.2500.1250.2500.5001.000
Strain05IS MRU#: 412006IS MRU#: 433407IS MRU#: 403308IS MRU#: 4108
µg/mLMICMFCMICMFCMICMFCMICMFC
FLZ312.500FS312.500FS156.250FS312.500FS
AmB1.95331.2501.9537.8133.90662.50015.62531.250
NYST62.500250.000125.000FS62.500FS31.250FS
CAS0.2500.5000.1250.5000.2502.0000.1250.250
Strain09IS MRU#: 403610IS MRU#: 408611IS MRU#: 547312IS MRU#: 5503
µg/mLMICMFCMICMFCMICMFCMICMFC
FLZ312.500FS312.500FS625.000FS312.500FS
AmB7.81331.2507.81331.2507.81362.5001.95331.250
NYST31.25062.50015.62531.2507.813125.00031.250125.000
CAS0.5002.0000.0630.1250.1250.2501.0004.000
The concentrations are in µg/mL. FS = Fungistatic.
Table
Table 2. List of predicted antigenic proteins that are present in the cell wall extract of C. parapsilosis.
Table 2. List of predicted antigenic proteins that are present in the cell wall extract of C. parapsilosis.
GeneProtein NamesLocalizationType
CPAR2_100640Uncharacterized proteinCytoplasmSoluble
CPAR2_104370Uncharacterized proteinNucleusSoluble
CPAR2_104690GTP-binding nuclear proteinCytoplasmSoluble
CPAR2_105980Uncharacterized proteinCytoplasmSoluble
CPAR2_106320Uncharacterized proteinCytoplasmSoluble
CPAR2_109010Uncharacterized proteinPlastidSoluble
CPAR2_110110HTH cro/C1-type domain-containing proteinNucleusSoluble
CPAR2_201550Glycine cleavage system H proteinMitochondrionSoluble
CPAR2_203410Uncharacterized proteinMitochondrionSoluble
CPAR2_204240Proteosome_alpha_1 domain-containing proteinNucleusSoluble
CPAR2_205620Ribosomal_S10 domain-containing proteinCytoplasmSoluble
CPAR2_207050Uncharacterized proteinCytoplasmSoluble
CPAR2_211070NET domain-containing proteinNucleusSoluble
CPAR2_212330Uncharacterized proteinCytoplasmSoluble
CPAR2_300430Uncharacterized proteinNucleusSoluble
CPAR2_302060Histone-glutamine methyltransferase NucleusSoluble
CPAR2_304080Adenylyl-sulfate kinase CytoplasmSoluble
CPAR2_401210Proliferating cell nuclear antigenNucleusSoluble
CPAR2_403290Uncharacterized proteinCytoplasmSoluble
CPAR2_404800Candida ALS N domain-containing proteinCell surfaceMembrane
CPAR2_405130Uncharacterized proteinMitochondrionMembrane
CPAR2_503400Pre-mRNA-processing protein 46 NucleusSoluble
CPAR2_503520Branched-chain-amino-acid aminotransferase CytoplasmSoluble
CPAR2_50417040S ribosomal protein S24CytoplasmSoluble
CPAR2_600900Uncharacterized proteinCytoplasmSoluble
CPAR2_601260CS domain-containing proteinNucleusSoluble
CPAR2_602580Uncharacterized proteinCytoplasmSoluble
CPAR2_701270Uncharacterized proteinEndoplasmic reticulumMembrane
CPAR2_701500Uncharacterized proteinCytoplasmSoluble
CPAR2_701770H/ACA ribonucleoprotein complex subunit NOP10 NucleusSoluble
CPAR2_703940Uncharacterized proteinExtracellularSoluble
CPAR2_800880Actin-related protein 2/3 complex subunit 4CytoplasmSoluble
CPAR2_802120ANAPC4_WD40 domain-containing proteinNucleusSoluble
CPAR2_805040Uncharacterized proteinExtracellularSoluble
All membrane and extracellular proteins are shown in bold.
Table
Table 3. Details of C. albicans orthologs of the C. parapsilosis antigenic proteins occurring in the membrane form or localized to extracellular space.
Table 3. Details of C. albicans orthologs of the C. parapsilosis antigenic proteins occurring in the membrane form or localized to extracellular space.
GeneProtein NamesC. albicans Ortholog GeneC. albicans Ortholog Protein Name
CPAR2_404800Candida ALS N domain-containing proteinALS7/C3_06320WAgglutinin-like protein 7
CPAR2_405130Uncharacterized proteinC3_02270WUncharacterized protein
CPAR2_701270Uncharacterized proteinPHO88/CR_09320CInorganic phosphate transport protein PHO88
CPAR2_703940Uncharacterized proteinC7_03860WUncharacterized protein
CPAR2_805040Uncharacterized proteinC1_10170WUncharacterized protein
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gong, X.; Srivastava, V.; Naicker, P.; Khan, A.; Ahmad, A. Candida parapsilosis Cell Wall Proteome Characterization and Effectiveness against Hematogenously Disseminated Candidiasis in a Murine Model. Vaccines 2023, 11, 674. https://doi.org/10.3390/vaccines11030674

AMA Style

Gong X, Srivastava V, Naicker P, Khan A, Ahmad A. Candida parapsilosis Cell Wall Proteome Characterization and Effectiveness against Hematogenously Disseminated Candidiasis in a Murine Model. Vaccines. 2023; 11(3):674. https://doi.org/10.3390/vaccines11030674

Chicago/Turabian Style

Gong, Xiaolong, Vartika Srivastava, Previn Naicker, Amber Khan, and Aijaz Ahmad. 2023. "Candida parapsilosis Cell Wall Proteome Characterization and Effectiveness against Hematogenously Disseminated Candidiasis in a Murine Model" Vaccines 11, no. 3: 674. https://doi.org/10.3390/vaccines11030674

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop